International Edition
Latest News
Health

STRATIFY-CVD Model Balances Blood Pressure Treatment Benefits and Harms Using UK Electronic Health Records

A new cardiovascular prediction model developed using millions of English electronic health records aims to balance the benefits of blood pressure treatment against potential medical harms, Nature reported. Researchers built the STRATIFY-CVD model using data from the Clinical…

STRATIFY-CVD Model Balances Blood Pressure Treatment Benefits and Harms Using UK Electronic Health Records

A new cardiovascular prediction model developed using millions of English electronic health records aims to balance the benefits of blood pressure treatment against potential medical harms, Nature reported.

Researchers built the STRATIFY-CVD model using data from the Clinical Practice Research Datalink, covering the period between January 1, 1998, and December 31, 2018. The protocol for this study was approved by CPRD’s Independent Scientific Advisory Committee in April 2025.

The analysis incorporated electronic health records corresponding to patients enrolled at an English general practice, provided they had hospital and mortality data linked within the CPRD spanning the timeframe of 1st January 1998 to 31st December 2018.

Study participants joined the cohort once their systolic blood pressure measurement hit or passed 130 mmHg following the 1st January 1998 start date. Patients with a systolic blood pressure reading equal to or greater than 180 mmHg were excluded because treatment benefits at that threshold outweigh adverse risks.

The model incorporates 18 distinct predictors derived from existing clinical risk assessment tools. These include patient demographics, traditional risk factors, and established comorbidities.

Investigators linked primary care metrics with mortality data from the Office for National Statistics and in-patient hospital diagnostic records from Hospital Episode Statistics. Socioeconomic deprivation data from the Index of Multiple Deprivation were also integrated into the evaluation.

To evaluate the trade-offs of intervention, the baseline risk of cardiovascular events was weighed against six specific adverse outcomes. These harms include hospitalisation with hypotension, syncope, falls, fracture, acute kidney injury, and diagnoses of hyperkalaemia.

Individuals left the cohort upon reaching the 31st December 2018 study end date, if they left a participating CPRD general practice, passed away, or developed the primary outcome under investigation. The absolute treatment effect was estimated across the cohort as events prevented or caused per 1,000 patients treated over a 10-year span.

The study used data from CPRD GOLD and CPRD Aurum, which were combined into a single analysis dataset representing the UK population.

The protocol for this study was approved by the CPRD Independent Scientific Advisory Committee (ISAC) under protocol number 25_004935.

Major cardiovascular disease outcomes encompassed non-fatal strokes (leaving out transient ischemic attacks) or heart attacks resulting in hospital admission, alongside any mortality attributable to cardiovascular disease.

About the author: Health Desk

Health Desk at Archynewsy.